Margarida Maia, PhD, science writer —

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

NMOSD, MS Tied to Higher Risk for Parkinson’s in South Korea

Patients with neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS), another disease that damages the protective myelin sheaths around nerve cells, are at higher risk than healthy individuals of also developing Parkinson’s disease (PD), a South Korean study found. The study, “Risk of Parkinson’s disease…

NF-kappaB Pathway May Be Useful Therapeutic Target for NMOSD

Astrocytes, star-shaped cells found around nerve cells, make an inflammation driver of neuromyelitis optica spectrum disorder (NMOSD) called interleukin-6 (IL-6) in part by gearing up a chain of reactions involving nuclear factor kappa B, or NF-kappaB, according to a study in rat cells. Researchers also observed that by blocking…

Analysis: First-line Rituximab Better Than MMF at Preventing Relapses

Rituximab may be a more effective immunosuppressive therapy for preventing a first relapse in people with neuromyelitis optica spectrum disorder (NMOSD) than mycophenolate mofetil (MMF), a new meta-analysis found. The anti-CD20 antibody rituximab, commonly used off-label in NMOSD, also appears to work better than azathioprine, though the results failed…

Enspryng Recommended for EU Approval for Patients, 12 and Older

A branch of the European Medicines Agency has recommended that Enspryng (satralizumab) be approved to treat patients, 12 and older, with neuromyelitis optica spectrum disorder (NMOSD), who carry antibodies against the aquaporin-4 protein (AQP4-IgG). The recommendation, made by the agency’s Committee for Medicinal Products for Human Use…